Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

bluebird bio

Main focus: Gene therapies and gene editing for the treatment of genetic diseases

Company stage: Clinical

Diseases (gene editing): Haemophilia and other severe genetic diseases

Genome editing tool: megaTAL

Funding stage: Public

Location: Cambridge, MA, USA



Gene editing partnerships: Novo Nordisk

bluebird bio develops novel gene and cancer therapies. The company is developing its proprietary megaTAL gene-editing technology, although it still has to disclose its first pre-clinical candidate derived from this. The company has a collaboration with Novo Nordisk to jointly develop next generation in vivo genome-editing treatments for genetic diseases, including haemophilia.


HashtagBluebird bio

Company: bluebird bio
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine